Form 4: Myriad Genetics CCO Awarded 226,804 RSUs

Myriad Genetics' Chief Commercial Officer, Brian J. Donnelly, was granted 226,804 restricted stock units, increasing his beneficial ownership to 624,338 shares.

Summary

• Brian J. Donnelly, Chief Commercial Officer of Myriad Genetics Inc. (MYGN), acquired 226,804 shares of common stock.
• The acquisition occurred on March 12, 2026, and was reported as a grant of time-based restricted stock units (RSUs).
• These RSUs were granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan.
• Each restricted stock unit represents a contingent right to receive one share of Myriad Genetics common stock.
• The RSUs are scheduled to vest in three equal annual installments, with the first installment vesting on the first anniversary of the grant date.
• Following this transaction, Brian J. Donnelly's beneficial ownership of Myriad Genetics common stock totals 624,338 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at retaining key talent and aligning management incentives with long-term company performance.

Positives

• The grant of 226,804 restricted stock units to the Chief Commercial Officer indicates continued investment in and retention of key management personnel.
• The three-year vesting schedule for the RSUs aligns management's long-term interests with shareholder value creation and company performance.

Future Outlook

The restricted stock units are structured to vest in three equal annual installments, beginning one year from the grant date, indicating a multi-year retention and performance alignment strategy for the Chief Commercial Officer.

Management Comments

• The grant of restricted stock units to the Chief Commercial Officer reflects the company's use of its 2017 Employee, Director and Consultant Equity Incentive Plan to incentivize key personnel.

Industry Context

StockSavvy.ai notes that equity grants, particularly restricted stock units with multi-year vesting, are a standard practice in the biotechnology and diagnostics industry to attract, retain, and motivate executive talent, aligning their performance with long-term company success. This is consistent with compensation strategies seen at peers like Exact Sciences or Guardant Health.

Comparison to Industry Standards

• The grant of restricted stock units with a multi-year vesting schedule is a common compensation practice in the biotech sector, similar to equity incentive plans at companies such as Exact Sciences (EXAS) or Illumina (ILMN) which use such grants to retain key executives and align their interests with long-term shareholder value.
• The specific amount granted would need to be compared against peer executive compensation packages relative to company size and performance to fully assess its alignment with industry standards.

Related Party Transactions

• The grant of restricted stock units to Chief Commercial Officer Brian J. Donnelly is a related party transaction, executed under the company's approved 2017 Employee, Director and Consultant Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Potential positive impact through improved management retention and alignment of executive interests with long-term company performance.
• Employees: May signal stability in executive leadership and the company's commitment to its equity incentive plans.

Next Steps

• The restricted stock units will vest in three equal annual installments, starting on March 12, 2027, and continuing on subsequent anniversaries.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive as part of their compensation package. While it aligns management's interests with shareholders, it does not provide new fundamental information to warrant a change in investment recommendation. Investors should continue to hold based on broader company performance and market conditions.

Keywords

Myriad Genetics, MYGN, Brian J Donnelly, Chief Commercial Officer, CCO, Restricted Stock Units, RSU, Equity Incentive Plan, Insider Transaction, Form 4